Suvratoxumab

Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin or Linezolid .

Suvratoxumab (5, 15, 45 mg/kg; i.p.; single) increases survival rates in an immunocompromised murine pneumonia model^[1].
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis reduces pulmonary damage and increases macrophage phagocytosis in mice^[1].
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis improves the effectiveness of antibiotic (vancomycin or linezolid) treatment in mice^[1].

References:
[1]. Hua L, et al. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother. 2015 Aug;59(8):4526-32.
[2]. Yu XQ, et al. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e01020-16.
[3]. Oganesyan V, et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80.